DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia
Year: 2019
Type: article
Abstract: The prognostic implications of DNMT3A genotype in T-cell acute lymphoblastic leukemia are incompletely understood. We performed comprehensive genetic and clinico-biological analyses of T-cell acute lymphoblastic leukemia patients with DNMT3A mutations treated during the GRAALL-2003 and -2005 studies. Eighteen of 198 cases (9.1%) had DNMT3A alterations. Two patients also had DNMT3A mutations in non-leukemic cell DNA, providing the first potential evidence of age-related clonal hematopoiesis in T-cell acute lymphoblastic leukemia. DNMT3A mutation was associated with older age (median 43.9 years vs. 29.4 years, P
Source: Haematologica
Authors: Jonathan Bond, Aurore Touzart, Stéphane Leprêtre, Carlos Graux, Mario Bargetzi, Ludovic Lhermitte, Guillaume Hypolite, Thibaut Leguay, Yosr Hicheri, Gaëlle Guillerm, Karin Bilger, Véronique Lhéritier, Mathilde Hunault, Françoise Huguet, Yves Chalandon, Norbert Ifrah, Elizabeth Macintyre, Hervé Dombret, Vahid Asnafi, Nicolas Boissel
Institutions: University College Dublin, Hôpital Necker-Enfants Malades, Inserm, Children's Health Ireland at Crumlin, Institut Necker Enfants Malades, Assistance Publique – Hôpitaux de Paris, National Children’s Research Centre, Université Paris Descartes, Centre Henri Becquerel, Université de Rouen Normandie, UCLouvain, Swiss Group For Clinical Cancer Research, Kantonsspital Aarau, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint Eloi, Centre Hospitalier Régional Universitaire de Brest, Hôpital d'Hautepierre, Hôpital Lyon Sud, Centre Hospitalier Universitaire d'Angers, Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, University Hospital of Geneva, Hôpital Saint-Louis, Université Paris Diderot, Recherche clinique appliquée à l'hématologie, Institut Universitaire d'Hématologie
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funder: Kay Kendall Leukaemia Fund
OpenAlex ID: W2910257591
